Ulocuplumab (anti-CXCR4), C-X-C 趋化因子受体 4 型抑制剂

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 小鼠(Mouse)
亚型: Human IgG4SP
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab175993-100μg	100μg	现货
Ab175993-1mg	1mg	现货
Ab175993-5mg	5mg	现货
Ab175993-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: CXCR4

Accession#:P61073 (7) Class A GPCR (8201) Cxcr4 (7) Gene ID:7852 (7)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Ulocuplumab (anti-CXCR4), C-X-C 趋化因子受体 4 型抑制剂
别名	乌洛单抗（抗 CXCR4）
英文别名	CXCR-4 \| CXC-R4 \| FB22 \| Fusin \| HM89 \| LAP-3 \| LCR1 \| LESTR \| Leukocyte-derived seven transmembrane domain receptor \| Lipopolysaccharide-associated protein 3 \| LPS-associated protein 3 \| NPYRL \| SDF-1 receptor \| Stromal cell-derived factor 1 receptor
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	CXCR4
种属反应性	人(Human),小鼠(Mouse)
偶联	Unconjugated
作用类型	抑制剂
作用机制	C-X-C 趋化因子受体 4 型抑制剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG4SP
轻链亚型	kappa
SDS-PAGE	26.7 kDa (Light Chain) & 52.5 kDa (Heavy Chain), under reducing conditions; 187.4 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1375830-34-4
分子类型	抗体

关联靶点（人）

CXCR4 Tclin CXC 趋化因子受体 4 型(C-X-C chemokine receptor type 4) (0 活性数据)

点击查看靶蛋白信息： CXCR4

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: Ulocuplumab (anti-CXCR4) (Ab175993)

Ulocuplumab (anti-CXCR4) (Ab175993) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling CXCR4 (red) with Ulocuplumab (anti-CXCR4) (Ab175993). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到5个结果

批号(Lot Number)	证书类型	货号
ZJ23F1101849	分析证书	Ab175993
ZJ23F1101850	分析证书	Ab175993
ZJ24F0911537	分析证书	Ab175993
ZJ24F0911536	分析证书	Ab175993
ZJ24F0911535	分析证书	Ab175993

可替换产品

引用文献

1. Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, Moser B. (1994) Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.. J Biol Chem, 269 (1): (232-7). [PMID:8276799]
2. Feng Y, Broder CC, Kennedy PE, Berger EA. (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.. Science, 272 (5263): (872-7). [PMID:8629022]
3. Gupta SK, Pillarisetti K. (1999) Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant.. J Immunol, 163 (5): (2368-72). [PMID:10452968]
4. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, Klotman ME, Diaz GA. (2003) Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease.. Nat Genet, 34 (1): (70-4). [PMID:12692554]
5. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A, Pei G, Manfredi JP, Fujii N, Broach JR, Peiper SC. (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists.. J Biol Chem, 277 (24515-24521). [PMID:11923301]
6. Di Salvo J, Koch GE, Johnson KE, Blake AD, Daugherty BL, DeMartino JA, Sirotina-Meisher A, Liu Y, Springer MS, Cascieri MA et al.. (2000) The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled states.. Eur J Pharmacol, 409 (2): (143-54). [PMID:11104827]
7. Herzog H, Hort YJ, Shine J, Selbie LA. (1993) Molecular cloning, characterization, and localization of the human homolog to the reported bovine NPY Y3 receptor: lack of NPY binding and activation.. DNA Cell Biol, 12 (6): (465-71). [PMID:8329116]
8. Jazin EE, Yoo H, Blomqvist AG, Yee F, Weng G, Walker MW, Salon J, Larhammar D, Wahlestedt C. (1993) A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells.. Regul Pept, 47 (3): (247-58). [PMID:8234909]
9. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC et al.. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.. Science, 330 (6007): (1066-71). [PMID:20929726]
10. Thoma G, Streiff MB, Kovarik J, Glickman F, Wagner T, Beerli C, Zerwes HG. (2008) Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.. J Med Chem, 51 (24): (7915-20). [PMID:19053768]
11. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, Wanska M, Greenberg J, Weiszmann J, Ge H, Tian H et al.. (2010) The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.. Bioorg Med Chem Lett, 20 (2): (493-8). [PMID:20005104]
12. Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, Labrecque J, Lau G, Mosi RM, Nelson KL et al.. (2006) Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.. Biochem Pharmacol, 72 (5): (588-96). [PMID:16815309]
13. Yu L, Cecil J, Peng SB, Schrementi J, Kovacevic S, Paul D, Su EW, Wang J. (2006) Identification and expression of novel isoforms of human stromal cell-derived factor 1.. Gene, 374 (174-9). [PMID:16626895]
14. Rueda P, Balabanian K, Lagane B, Staropoli I, Chow K, Levoye A, Laguri C, Sadir R, Delaunay T, Izquierdo E et al.. (2008) The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins.. PLoS ONE, 3 (7): (e2543). [PMID:18648536]
15. Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, Heveker N, Volkman BF, Dwinell MB. (2011) Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways.. Proc Natl Acad Sci USA, 108 (43): (17655-60). [PMID:21990345]
16. Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner 3rd JC, Basnet H, Sakmar TP, Volkman BF. (2008) Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12.. Sci Signal, 1 (37): (ra4). [PMID:18799424]
17. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD, Clark-Lewis I. (1997) Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1.. EMBO J, 16 (23): (6996-7007). [PMID:9384579]
18. Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Manning RJ, Tripsas C, Patterson CJ, Sheehy P et al.. (2014) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.. Blood, 123 (11): (1637-46). [PMID:24366360]
19. Wu KJ, Yu SJ, Shia KS, Wu CH, Song JS, Kuan HH, Yeh KC, Chen CT, Bae E, Wang Y. (2017) A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.. Cell Transplant, 26 (4): (571-583). [PMID:27938478]
20. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.. Nature, 382 (6594): (829-33). [PMID:8752280]
21. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF et al.. (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.. Nature, 382 (6594): (833-5). [PMID:8752281]
22. Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O, Lebbe C, Kerob D, Dupuy A, Hermine O et al.. (2005) WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12.. Blood, 105 (6): (2449-57). [PMID:15536153]
23. Miller EJ, Jecs E, Truax VM, Katzman BM, Tahirovic YA, Wilson RJ, Kuo KM, Kim MB, Nguyen HH, Saindane MT et al.. (2018) Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.. J Med Chem, 61 (3): (946-979). [PMID:29350534]
24. Karpova D, Bräuninger S, Wiercinska E, Krämer A, Stock B, Graff J, Martin H, Wach A, Escot C, Douglas G et al.. (2017) Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial.. J Transl Med, 15 (1): (2). [PMID:28049490]
25. Sohy D, Parmentier M, Springael JY.. (2007) Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.. J Biol Chem, 282 (41): (30062-30069). [PMID:17715128] [10.1074/jbc.m705302200]
26. Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO.. (2009) 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.. Bioorg Med Chem, 17 (4): (1486-1493). [PMID:19188071] [10.1016/j.bmc.2009.01.014]
27. Chen JJ, Cole DC, Ciszewski G, Crouse K, Ellingboe JW, Nowak P, Tawa GJ, Berstein G, Li W.. (2010) Identification of a new class of small molecule C5a receptor antagonists.. Bioorg Med Chem Lett, 20 (2): (662-664). [PMID:20004096] [10.1016/j.bmcl.2009.11.058]
28. Zhu A, Zhan W, Liang Z, Yoon Y, Yang H, Grossniklaus HE, Xu J, Rojas M, Lockwood M, Snyder JP, Liotta DC, Shim H.. (2010) Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity.. J Med Chem, 53 (24): (8556-8568). [PMID:21105715] [10.1021/jm100786g]
29. Ukani R, Lewis TC, Day TP, Wu W, Malladi SS, Warshakoon HJ, David SA.. (2012) Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.. Bioorg Med Chem Lett, 22 (1): (293-295). [PMID:22104149] [10.1016/j.bmcl.2011.11.014]
30. Lefrançois M, Lefebvre MR, Saint-Onge G, Boulais PE, Lamothe S, Leduc R, Lavigne P, Heveker N, Escher E.. (2011) Agonists for the Chemokine Receptor CXCR4.. ACS Med Chem Lett, 2 (8): (597-602). [PMID:21841963] [10.1021/ml200084n]
31. Gasparik V, Daubeuf F, Hachet-Haas M, Rohmer F, Gizzi P, Haiech J, Galzi JL, Hibert M, Bonnet D, Frossard N.. (2012) Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo.. ACS Med Chem Lett, 3 (1): (10-14). [PMID:24900366] [10.1021/ml200017d]
32. Wilkinson RA, Pincus SH, Song K, Shepard JB, Weaver AJ, Labib ME, Teintze M.. (2013) Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.. Bioorg Med Chem Lett, 23 (7): (2197-2201). [PMID:23434419] [10.1016/j.bmcl.2013.01.107]
33. Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.. (2013) Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.. J Med Chem, 56 (20): (8049-8065). [PMID:24090135] [10.1021/jm401101p]
34. Zhao H, Prosser AR, Liotta DC, Wilson LJ.. (2015) Discovery of novel N-aryl piperazine CXCR4 antagonists.. Bioorg Med Chem Lett, 25 (21): (4950-4955). [PMID:25935642] [10.1016/j.bmcl.2015.04.036]
35. Zhan P, Pannecouque C, De Clercq E, Liu X.. (2016) Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.. J Med Chem, 59 (7): (2849-2878). [PMID:26509831] [10.1021/acs.jmedchem.5b00497]
36. Bai R, Liang Z, Yoon Y, Liu S, Gaines T, Oum Y, Shi Q, Mooring SR, Shim H.. (2016) Symmetrical bis-tertiary amines as novel CXCR4 inhibitors.. Eur J Med Chem, 118 (340-350). [PMID:27179215] [10.1016/j.ejmech.2016.04.040]
37. Di Maro S, Trotta AM, Brancaccio D, Di Leva FS, La Pietra V, Ieranò C, Napolitano M, Portella L, D'Alterio C, Siciliano RA, Sementa D, Tomassi S, Carotenuto A, Novellino E, Scala S, Marinelli L.. (2016) Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.. J Med Chem, 59 (18): (8369-8380). [PMID:27571038] [10.1021/acs.jmedchem.6b00695]
38. Bai R, Shi Q, Liang Z, Yoon Y, Han Y, Feng A, Liu S, Oum Y, Yun CC, Shim H.. (2017) Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.. Eur J Med Chem, 126 (464-475). [PMID:27914361] [10.1016/j.ejmech.2016.11.026]
39. Wu CH, Song JS, Kuan HH, Wu SH, Chou MC, Jan JJ, Tsou LK, Ke YY, Chen CT, Yeh KC, Wang SY, Yeh TK, Tseng CT, Huang CL, Wu MH, Kuo PC, Lee CJ, Shia KS.. (2018) Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.. J Med Chem, 61 (3): (818-833). [PMID:29314840] [10.1021/acs.jmedchem.7b01322]
40. Bai R, Liang Z, Yoon Y, Salgado E, Feng A, Gurbani S, Shim H.. (2017) Novel anti-inflammatory agents targeting CXCR4: Design, synthesis, biological evaluation and preliminary pharmacokinetic study.. Eur J Med Chem, 136 (360-371). [PMID:28521261] [10.1016/j.ejmech.2017.05.030]
41. Li Z, Wang Y, Fu C, Wang X, Wang JJ, Zhang Y, Zhou D, Zhao Y, Luo L, Ma H, Lu W, Zheng J, Zhang X.. (2018) Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.. Eur J Med Chem, 149 (30-44). [PMID:29494843] [10.1016/j.ejmech.2018.02.042]
42. Peng D, Cao B, Zhou YJ, Long YQ.. (2018) The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.. Eur J Med Chem, 149 (148-169). [PMID:29500940] [10.1016/j.ejmech.2018.02.043]
43. Bai R, Sun J, Liang Z, Yoon Y, Salgado E, Feng A, Oum Y, Xie Y, Shim H.. (2018) Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives.. Eur J Med Chem, 150 (195-205). [PMID:29529500] [10.1016/j.ejmech.2018.02.085]
44. Wu R, Yu W, Yao C, Liang Z, Yoon Y, Xie Y, Shim H, Bai R.. (2020) Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.. Eur J Med Chem, 185 (111823-111823). [PMID:31698158] [10.1016/j.ejmech.2019.111823]
45. Gaines T, Garcia F, Virani S, Liang Z, Yoon Y, Oum YH, Shim H, Mooring SR.. (2019) Synthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors.. Eur J Med Chem, 181 (111562-111562). [PMID:31377592] [10.1016/j.ejmech.2019.111562]
46. Imaizumi T, Kobayashi A, Otsubo S, Komai M, Magara M, Otsubo N.. (2019) The discovery and optimization of a series of 2-aminobenzoxazole derivatives as ChemR23 inhibitors.. Bioorg Med Chem, 27 (21): (115091-115091). [PMID:31521459] [10.1016/j.bmc.2019.115091]
47. Sakyiamah MM, Kobayakawa T, Fujino M, Konno M, Narumi T, Tanaka T, Nomura W, Yamamoto N, Murakami T, Tamamura H.. (2019) Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands.. Bioorg Med Chem, 27 (6): (1130-1138). [PMID:30772128] [10.1016/j.bmc.2019.02.013]
48. Virani S, Liang Z, Yoon Y, Shim H, Mooring SR.. (2019) Synthesis and evaluation of 2,5-diamino and 2,5-dianilinomethyl pyridine analogues as potential CXCR4 antagonists.. Bioorg Med Chem Lett, 29 (2): (220-224). [PMID:30514601] [10.1016/j.bmcl.2018.11.052]
49. Yang Y, Gao M, Zhang Q, Zhang C, Yang X, Huang Z, An J.. (2016) Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4.. Bioorg Med Chem, 24 (21): (5393-5399). [PMID:27658790] [10.1016/j.bmc.2016.08.062]
50. Peddibhotla S, Hershberger PM, Jason Kirby R, Sugarman E, Maloney PR, Hampton Sessions E, Divlianska D, Morfa CJ, Terry D, Pinkerton AB, Smith LH, Malany S.. (2020) Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma.. Bioorg Med Chem Lett, 30 (4): (126899-126899). [PMID:31882297] [10.1016/j.bmcl.2019.126899]
51. Menhaji-Klotz E, Ward J, Brown JA, Loria PM, Tan C, Hesp KD, Riccardi KA, Litchfield J, Boehm M.. (2020) Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity.. ACS Med Chem Lett, 11 (6): (1330-1334). [PMID:32551020] [10.1021/acsmedchemlett.0c00163]
52. Richard-Bildstein S,Aissaoui H,Pothier J,Schäfer G,Gnerre C,Lindenberg E,Lehembre F,Pouzol L,Guerry P. (2020) Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.. J Med Chem, 63 (24): (15864-15882). [PMID:33314938] [10.1021/acs.jmedchem.0c01588]
53. Oum YH,Kell SA,Yoon Y,Liang Z,Burger P,Shim H. (2020) Discovery of novel aminopiperidinyl amide CXCR4 modulators through virtual screening and rational drug design.. Eur J Med Chem, 201 (112479-112479). [PMID:32534343] [10.1016/j.ejmech.2020.112479]
54. Li Z,Wang X,Lin Y,Wang Y,Wu S,Xia K,Xu C,Ma H,Zheng J,Luo L,Zhu F,He S,Zhang X. (2020) Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.. Eur J Med Chem, 205 (112537-112537). [PMID:32768738] [10.1016/j.ejmech.2020.112537]
55. Xue D,Chen W,Neamati N. (2020) Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists.. Eur J Med Chem, 204 (112387-112387). [PMID:32829163] [10.1016/j.ejmech.2020.112387]
56. Nomura, H H, Nielsen, B W BW and Matsushima, K K.. (1993) Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors.. International immunology, [PMID:7505609]
57. Federsppiel, B B and 6 more authors.. (1993) Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen.. Genomics, [PMID:8325644]
58. Lapham, C K CK and 5 more authors.. (1996) Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines.. Science (New York, N.Y.), (25): [PMID:8849450]
59. Endres, M J MJ and 15 more authors.. (1996) CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.. Cell, (15): [PMID:8929542]
60. Wegner, S A SA and 5 more authors.. (1998) Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1.. The Journal of biological chemistry, (20): [PMID:9468539]
61. Caruz, A A and 7 more authors.. (1998) Genomic organization and promoter characterization of human CXCR4 gene.. FEBS letters, (17): [PMID:9599023]
62. Frodl, R R, Gierschik, P P and Moepps, B B.. Genomic organization and expression of the CXCR4 gene in mouse and man: absence of a splice variant corresponding to mouse CXCR4-B in human tissues.. Journal of receptor and signal transduction research, [PMID:9879064]
63. Doranz, B J BJ and 8 more authors.. (1999) Identification of CXCR4 domains that support coreceptor and chemokine receptor functions.. Journal of virology, [PMID:10074122]
64. Farzan, M M and 8 more authors.. (1999) Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.. Cell, (5): [PMID:10089882]
65. Xiao, L L and 7 more authors.. (1999) Partial resistance to infection by R5X4 primary HIV type 1 isolates in an exposed-uninfected individual homozygous for CCR5 32-base pair deletion.. AIDS research and human retroviruses, (1): [PMID:10480633]
66. Cheng, Z J ZJ and 7 more authors.. (2000) beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4.. The Journal of biological chemistry, (28): [PMID:10644702]
67. Chabot, D J DJ, Chen, H H, Dimitrov, D S DS and Broder, C C CC.. (2000) N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.. Journal of virology, [PMID:10756055]
68. Xiao, H H and 6 more authors.. (2000) Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.. Proceedings of the National Academy of Sciences of the United States of America, (10): [PMID:11027346]
69. Triantafilou, K K, Triantafilou, M M and Dedrick, R L RL.. (2001) A CD14-independent LPS receptor cluster.. Nature immunology, [PMID:11276205]
70. Litovchick, A A, Lapidot, A A, Eisenstein, M M, Kalinkovich, A A and Borkow, G G.. (2001) Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities.. Biochemistry, (25): [PMID:11747436]
71. Farzan, Michael M and 6 more authors.. (2002) The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1 entry.. The Journal of biological chemistry, (16): [PMID:12034737]
72. Marchese, Adriano A and 5 more authors.. (2003) The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4.. Developmental cell, [PMID:14602072]
73. Forde, Sinead S and 7 more authors.. (2007) Endolyn (CD164) modulates the CXCL12-mediated migration of umbilical cord blood CD133+ cells.. Blood, (1): [PMID:17077324]
74. Seibert, Christoph C and 5 more authors.. (2008) Sequential tyrosine sulfation of CXCR4 by tyrosylprotein sulfotransferases.. Biochemistry, (28): [PMID:18834145]
75. Bhandari, Deepali D, Robia, Seth L SL and Marchese, Adriano A.. (2009) The E3 ubiquitin ligase atrophin interacting protein 4 binds directly to the chemokine receptor CXCR4 via a novel WW domain-mediated interaction.. Molecular biology of the cell, [PMID:19116316]
76. Walenkamp, Annemiek M E AM and 7 more authors.. (2009) Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration.. Neoplasia (New York, N.Y.), [PMID:19308288]
77. Busillo, John M JM and 5 more authors.. (2010) Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling.. The Journal of biological chemistry, (5): [PMID:20048153]
78. Pérez-Martínez, Manuel M and 14 more authors.. (2010) F-actin-binding protein drebrin regulates CXCR4 recruitment to the immune synapse.. Journal of cell science, (1): [PMID:20215400]
79. Saini, Vikas V, Marchese, Adriano A and Majetschak, Matthias M.. (2010) CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin.. The Journal of biological chemistry, (14): [PMID:20228059]
80. Malik, Rohit R and Marchese, Adriano A.. (2010) Arrestin-2 interacts with the endosomal sorting complex required for transport machinery to modulate endosomal sorting of CXCR4.. Molecular biology of the cell, (15): [PMID:20505072]
81. Cheng, Shi-Bin SB, Quinn, Jeffrey A JA, Graeber, Carl T CT and Filardo, Edward J EJ.. (2011) Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway.. The Journal of biological chemistry, (24): [PMID:21540189]
82. Tadagaki, Kenjiro K and 7 more authors.. (2012) Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and CXCR4 impairing their HIV coreceptor activity.. Blood, (24): [PMID:22496149]
83. Jujo, Kentaro K and 17 more authors.. (2013) CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism.. Circulation, (1): [PMID:23204107]
84. Treon, Steven P SP and 5 more authors.. (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.. Blood, (1): [PMID:24553177]
85. Cao, Y Y and 11 more authors.. (2015) The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.. Leukemia, [PMID:24912431]
86. Qin, Ling L and 12 more authors.. (2015) Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine.. Science (New York, N.Y.), (6): [PMID:25612609]
87. Lear, Travis T and 6 more authors.. (2017) RING finger protein 113A regulates C-X-C chemokine receptor type 4 stability and signaling.. American journal of physiology. Cell physiology, (1): [PMID:28978524]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Ulocuplumab (anti-CXCR4), C-X-C 趋化因子受体 4 型抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器